A number of hurdles have to be overcome for efficient and specific gene therapy approaches. Here, we report on two different strategies that should lead to an improvement of current protocols. A strategy is presented to tag unique chromosomal integration sites by means of retroviral infection, which can be reused for exchange with the gene of interest by action of site-specific recombinases. Targeting exchange is achieved in one step with 100% efficiency by a stringent positive selection, which makes further screening superfluous. With this strategy a predictable gene expression is obtained for foreign genes integrated into a predefined chromatin structure. A second approach aims at the stabilization of mouse retroviruses towards human serum which is a prerequisite for in vivo gene therapy protocols. To stabilize murine leukemia virus-based retroviruses against human serum, complement regulatory proteins were fused to the retroviral ENV proteins. This resulted in infectious and human complement-protected particles.

Keywords:
Gene therapy, Stem cells, Retrovirus, Complement resistance, Gene targeting
1.
Araki, K., M. Araki, K. Yamamura (1997) Targeted integration of DNA using mutant lox sites in embryonic stem cells. Nucleic Acids Res 25: 868–872.
2.
Baubonis, W., B. Sauer (1993) Genomic targeting with purified Cre recombinase. Nucleic Acids Res 21: 2025–2029.
3.
Choulika, A., V. Guyot, J.-F. Nicoles (1996) Transfer of a single gene-containing long terminal repeat into the genome of mammalian cells by a retroviral vector carrying the cre gene and the loxP site. J Virol 70: 1792–1798.
4.
Karreman, S., H. Hauser, C. Karreman (1996) On the use of double FLP recognition targets (FRTs) in the LTR of retroviruses for the construction of high producer cell lines. Nucleic Acids Res 24: 1616–1624.
5.
Miyao, Y., K. Ikenaka, H. Kishima, M. Tamura, K. Nikamura, M. Kurumi, T. Hayakawa, K. Shimizu (1997) FUT-175, a synthetic inhibitor of the complement pathway, protects against the inactivation of infectious retroviruses by human serum. Hum Gene Ther 8: 1575–1583.
6.
O’Gorman, S., D.T. Fox, G.M. Wahl (1991) Recombinase mediated gene activation and site-specific integration in mammalian cells. Science 251: 1351–1355.
7.
Penisero, M.N., C.A. Wysocki, K. Nader, G.E. Kikuchi (1996) Development of amphotropic murine retrovirus vectors resistant to inactivation by human serum. Hum Gene Ther 7: 1095–1101.
8.
Rother, R.P., S.P. Squinto (1996) The α-galactosyl epitope: A sugar coating that makes viruses and cells unpalatable. Cell 86: 185–188.
9.
Schlake, T., J. Bode (1994) Use of mutated FLP recognition target (FRT) sites for the exchange of expression cassettes at defined chromosomal loci. Biochemistry 33: 12746–12751.
10.
Seibler, J., J. Bode (1997) Double-reciprocal crossover mediated by FLP-recombinase: A concept and an assay. Biochemistry 36: 1740–1747.
11.
Welsh, R.M., N.R. Cooper, F.C. Jensen, M.B.A. Oldstone (1975) Human serum lyses RNA tumor viruses. Nature 257: 612–614.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.